Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 5NIH 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Melanoma 2Prostatic Neoplasms 1

Interventions

Specimen Handling 180Cyclophosphamide 161Magnetic Resonance Spectroscopy 153Biopsy 128Radiotherapy 109Cisplatin 109Bevacizumab 107Carboplatin 101Doxorubicin 96Paclitaxel 94Etoposide 87Filgrastim 81aldesleukin 78Gemcitabine 73Vincristine 72Fluorouracil 72Leucovorin 62fludarabine phosphate 58Docetaxel 58Bortezomib 54Sorafenib 53Cytarabine 51Methotrexate 50Taxes 49Immunoglobulin G 49Disulfides 49Rituximab 48Oxaliplatin 48sargramostim 47Prednisone 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NIH × Protein Subunit Vaccines × Clear all
NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
50 enrolled 13 charts
Dermatologic

Melanoma

NCT00109811 2013-01-23

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
32 enrolled
Genitourinary

Prostatic Neoplasms

NCT00005949 2013-01-16

Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡